VPC
NRIX icon

Vestal Point Capital’s Nurix Therapeutics NRIX Stock Holding History

Vestal Point Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101M Buy
6,500,000
+1,810,000
+39% +$30M 2.82% 9
2025
Q4 		$89M Buy
4,690,000
+1,215,000
+35% +$17.5M 3.02% 7
2025
Q3 		$32.1M Buy
3,475,000
+1,475,000
+74% +$15.3M 1.45% 27
2025
Q2 		$22.8M Buy
2,000,000
+874,448
+78% +$9.45M 1.2% 33
2025
Q1 		$13.4M Buy
1,125,552
+640,552
+132% +$10.7M 0.95% 34
2024
Q4 		$9.14M Buy
485,000
+60,000
+14% +$1.38M 0.54% 45
2024
Q3 		$9.55M Sell
425,000
-75,000
-15% -$1.7M 0.72% 35
2024
Q2 		$10.4M Buy
+500,000
New +$7.79M 0.78% 34

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vestal Point Capital's NRIX Position: Q1 2026 in Review

Vestal Point Capital increased its Nurix Therapeutics (NRIX) stake by 39% in Q1 2026, buying an estimated $30M and bringing the position to 6,500,000 shares worth $101M. The position accounts for 2.82% of the portfolio, ranked #9.

Vestal Point Capital first reported a position in NRIX in Q2 2024 and has held it in 8 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Vestal Point Capital held 6,500,000 shares of Nurix Therapeutics worth $101M as of Q1 2026.
  • Vestal Point Capital bought 1,810,000 Nurix Therapeutics shares in Q1 2026, an estimated $30M.
  • Nurix Therapeutics made up 2.82% of Vestal Point Capital's portfolio in Q1 2026, its #9 holding.
  • Vestal Point Capital first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.